PB1023 is a recombinant GLP-1 analogue genetically fused to our ELP biopolymer that is designed as a once-weekly treatment for hyperglycemia associated with type 2 diabetes. In a Phase 2a multiple ascending dose study, PB1023 demonstrated a prolonged effect on glucose control, which was maintained between weekly doses of the drug.

PhaseBio subsequently conducted a multi-center Phase 2b study in approximately 600 patients over 20 weeks to compare several doses of PB1023 against placebo and the active comparator, Victoza® (liraglutide, Novo Nordisk). PB1023 was administered once weekly, whereas Victoza® must be administered daily. Although PB1023 showed a significant reduction in HbA1c compared to placebo, the reduction was less than that seen with Victoza®.

PhaseBio is no longer pursuing PB1023 due to changes in the competitive environment for the treatment of type 2 diabetes.